Create a better world with artificial intelligence technology

Post Details
AIDOT, a leader in artificial intelligence systems for cervical cancer diagnosis, is heading to the Chinese market.
aidot (ip:)
  • Rate 0points  
  • Date 2022-01-19
  • Recommend Recommend
  • View 100

Watch the news video

Founded in June 2014, AIDOT's Cerviray AI is an artificial intelligence-based cervical cancer remote reading system. Cerviray AI is equipped with AIDOT-NETv1, an AI algorithm developed with AIDOT's own technology, and the system was developed through joint research with two of the best hospitals in Korea, Seoul National University Bundang Hospital and Anam Korea University Hospital.

Over the past year, AIDOT has collaborated with large hospitals, examination centers, and various companies that provide medical facilities in China, and all of the joint companies have judged that AIDOT products are sufficient to enter the Chinese market. Currently, AIDOT is further considering various methods to deploy products to hospitals directly under the health authorities, secondary and tertiary large hospitals, and examination centers.

AIDOT established a subsidiary in Beijing, China in 2017, and a joint venture in Shenzhen in 2020. In addition to Cerviray AI products, AIDOT includes a 'Sonodot AI system' based on carotid ultrasound, a stroke pre-diagnosis device 'Naodot AI system', and a 'Gigadot AI system' that enables real-time diagnosis of digestive system. In addition, AIDOT is currently developing an AI system that diagnoses chronic alcoholic liver disease.

2021-11-30 / NEWSPIM / 주옥함 기자

Password Please enter your password to remove or edit this message.
Edit Comment

Password :

/ byte

Password : Submit Cancel

Add Comment
Add a commentName : Password : View Reply

Combination in 10-16 characters containing at least two of the followings: upper and lower case letters/numbers/special letters

/ byte

Please type without any spaces. (case sensitive)

Comments can be added by Member only


© 2020 AIDOT. All rights reserved.